HZNP News and Press, Horizon Therapeutics Public Limited Company From 06/22/23

-- At Week 24, 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with 11% of patients receiving placebo -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline results from its randomized, double-mas...

2023-06-20 21:39:46 ET Summary John Paulson's 13F portfolio value increased by around 8% from approximately $1.11B to $1.20B in Q1 2023. The top five positions in the portfolio are Bausch Health, Brightsphere Investment Group, Novagold, Perpetua Resources, and Horizon Therapeutics...

2023-06-19 09:00:00 ET Summary Tech stocks have staged a massive comeback in 2023, but value investors should consider looking into currently unloved sectors like healthcare. The healthcare sector has underperformed in 2023, but the long-term outlook remains solid despite near-ter...

-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful improvement in proptosis (≥2 mm) compared with 25% of placebo patients -- -- Proportion of ...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among those treated with TEPEZZA. TEPEZZA is the first and only medicine approved by the U....

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “ Irish Takeover Rules ”), Horizon confirms that, as of the close of business on June 9, 2023, Horizon’s issued ordinary share capital is comprised of 228,928,661 ordinary shares...

-- Findings published in the Multiple Sclerosis Journal provide early validation of a process that could inform new clinical standards to improve attack diagnosis and treatment decision-making -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis f...

2023-06-09 14:52:57 ET Seagen ( NASDAQ: SGEN ) rose 1.2% ahead of a Monday deadline for an antitrust initial review of its planned $43 billion sale to Pfizer ( NYSE: PFE ). The Hart-Scott-Rodino deadline for the Federal Trade Commission's initial look at the acquisit...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced its partnership for the 2023 KPMG Women’s Irish Open held at Dromoland Castle from August 31 to September 3. The leading Ladies European Tour (LET) event tees up a week prior to the Horizon Irish Open and will draw Europe's leading pr...

-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being treated with TEPEZZA on Friday, June 16 at 10:15 a.m. CT -- Horizon Therapeutics p...